ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Sagimet Biosciences Receives Fast Track Designation from FDA for NASH Treatment
March 24, 2021Sagimet Biosciences announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to TVB-2640 for the treatment of patients with NASH. -
FASN Inhibitor ASC40 Demonstrates Positive Phase 2 Topline Clinical Results from China Cohort of Patients with NASH
March 09, 2021Gannex Pharma Co., Ltd., a wholly-owned company of Ascletis Pharma Inc., and Sagimet Biosciences Inc. jointly announced today positive topline results from the China cohort of a Phase 2 randomized, placebo-controlled clinical trial of oral ...
Pharma Sources Insight January 2025
